Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross Blue Shield - Iowa IVIG Prior Auth Poli…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - IowaPolicy 05.01.17

    Intravenous Immune Globulin (IVIG) — indications and authorization criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.01.17 alerts

    Get alerted when Policy 05.01.17 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This section of the IVIG policy lists specific clinical indications and the authorization durations/criteria for intravenous immune globulin therapy for members of Blue Cross Blue Shield - Iowa. It affects providers requesting prior authorization for IVIG for the listed diagnoses.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyIntravenous Immune Globulin (IVIG) — indications and authorization criteria
    Policy CodePolicy 05.01.17
    Change TypeNo material changes
    Effective DateAugust 28, 2026
    Last ReviewAug 28, 2026
    Next Review DateJune 1, 2026
    Key ActionObtain prior authorization with required diagnostic documentation and supporting clinical evidence (including IgG levels and timing) before IVIG is approved.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~20distinct indications listed
    6 monthstypical initial authorization
    1–2 monthsshort authorization windows
    <400 mg/dLIgG threshold used
    ~20HCPCS/J‑codes listed
    2appendices

    Coverage Criteria and Authorization Durations

    Prophylaxis of Bacterial Infections in BMT/HSCT Recipients

    Initial authorization of 6 months may be granted when ALL of the following are met:

    BMT/HSCT prophylaxis criteria: a) IG is prescribed for prophylaxis of bacterial infections; AND b) Either: i) IG is requested within the first 100 days post-transplant OR ii) member has a pretreatment serum IgG < 400 mg/dL.

    Re-authorization of 6 months may be granted when a reduction in the frequency of bacterial infections has been demonstrated since initiation of IG therapy.

    Multifocal Motor Neuropathy (MMN)

    Initial authorization of 3 months may be granted when ALL of the following are met:

    MMN initial criteria: a) Progressive, multifocal, asymmetrical weakness without objective sensory loss in 2 or more nerves for at least 1 month; AND b) Diagnosis confirmed by electrodiagnostic studies.

    Re-authorization of 6 months may be granted when significant improvement in disability and maintenance of improvement have occurred since initiation of IG therapy.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyIntravenous Immune Globulin (IVIG) — indications and authorization criteria
    Policy CodePolicy 05.01.17
    Change TypeNo material changes
    Effective DateAugust 28, 2026
    Last ReviewAug 28, 2026
    Next Review DateJune 1, 2026
    Key ActionObtain prior authorization with required diagnostic documentation and supporting clinical evidence (including IgG levels and timing) before IVIG is approved.
    SourceLink
    On This Page
    Coverage Criteria and Authorization DurationsBilling and CodingProvider Requirements, Prior Authorization, and DocumentationBackgroundDefinitions and Appendix References

    Guillain-Barre Syndrome (GBS)

    Authorization of 2 months total may be granted when ALL of the following are met:

    GBS criteria: a) Member has severe disease with significant weakness (e.g., inability to stand or walk without aid, respiratory weakness); AND b) Onset of neurologic symptoms occurred less than 4 weeks from the anticipated start of therapy.< 4 weeks

    Lambert-Eaton Myasthenic Syndrome (LEMS)

    Initial authorization of 6 months may be granted when ALL of the following are met:

    LEMS criteria: a) Diagnosis confirmed by either neurophysiology studies (e.g., electromyography) OR a positive anti-P/Q type voltage-gated calcium channel antibody test; AND b) Anticholinesterases (e.g., pyridostigmine) and amifampridine (e.g., 3,4-diaminopyridine phosphate, Firdapse) have been tried but were unsuccessful or not tolerated; AND c) Weakness is severe or there is difficulty with venous access for plasmapheresis.

    Re-authorization of 6 months may be granted when member is responding to therapy (stability or improvement).

    Kawasaki Syndrome

    Authorization of 1 month may be granted for pediatric members with Kawasaki syndrome.

    Kawasaki: Pediatric members with Kawasaki syndrome may receive 1 month authorization.

    Fetal/Neonatal Alloimmune Thrombocytopenia (F/NAIT)

    Authorization of 6 months may be granted for treatment of F/NAIT.

    F/NAIT: Authorization of 6 months for treatment of fetal/neonatal alloimmune thrombocytopenia (F/NAIT).

    Parvovirus B19-induced Pure Red Cell Aplasia (PRCA)

    Authorization of 6 months may be granted when the following are met:

    PRCA: Severe, refractory anemia associated with bone marrow suppression with documented parvovirus B19 viremia.

    Stiff-person Syndrome

    Authorization of 6 months may be granted when ALL of the following are met:

    Stiff-person: a) Diagnosis confirmed by anti-glutamic acid decarboxylase (GAD) antibody testing; AND b) Inadequate response to first-line treatment (benzodiazepines and/or baclofen).

    Immune Checkpoint Inhibitor-related Toxicities

    Authorization of 1 month may be granted when ALL of the following are met:

    ICI toxicities: 1) Member has experienced a moderate or severe adverse event to a PD-1 or PD-L1 inhibitor; AND 2) The offending medication has been held or discontinued; AND 3) Member has experienced one or more listed severe adverse events (e.g., myocarditis, bullous dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, pneumonitis, myasthenia gravis, peripheral neuropathy, encephalitis, transverse myelitis, severe inflammatory arthritis, Guillain-Barre syndrome, or steroid-refractory myalgias/myositis).

    Acquired Red Cell Aplasia

    Authorization of 6 months may be granted for acquired red cell aplasia.

    Acquired red cell aplasia: Authorization of 6 months for acquired red cell aplasia.

    Acute Disseminated Encephalomyelitis

    Authorization of 6 months may be granted when ALL of the following are met:

    ADEM: Acute disseminated encephalomyelitis in members who have had an insufficient response to or a contraindication to intravenous corticosteroid treatment.

    Autoimmune Mucocutaneous Blistering Disease

    Authorization of 6 months may be granted when ALL of the following are met:

    Blistering disease: 1) Diagnosis proven by biopsy and confirmed by pathology report; AND 2) Condition is rapidly progressing, extensive or debilitating; AND 3) Member has failed or experienced significant complications from standard treatment (corticosteroids, immunosuppressive agents).

    Includes pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita.

    Autoimmune Hemolytic Anemia

    Authorization of 6 months may be granted for warm-type autoimmune hemolytic anemia when the following are met:

    AIHA: Member does not respond to or has a contraindication to corticosteroids or splenectomy.

    Autoimmune Neutropenia

    Authorization of 6 months may be granted when the following are met:

    Autoimmune neutropenia: Treatment with GCSF (granulocyte colony stimulating factor) is not appropriate.

    Birdshot Retinochoroidopathy

    Authorization of 6 months may be granted for birdshot retinochoroidopathy that is not responsive to immunosuppressives.

    Birdshot: Not responsive to immunosuppressives (e.g., corticosteroids, cyclosporine).

    BK Virus Associated Nephropathy

    Authorization of 6 months may be granted for BK virus associated nephropathy.

    BK virus nephropathy: Authorization of 6 months for BK virus associated nephropathy.

    Churg-Strauss Syndrome

    Authorization of 6 months may be granted when ALL of the following are met:

    Churg-Strauss: Severe, active Churg-Strauss syndrome as adjunctive therapy for members who have experienced failure, intolerance, or are contraindicated to other interventions.

    Enteroviral Meningoencephalitis

    Authorization of 6 months may be granted for severe cases of enteroviral meningoencephalitis.

    Enteroviral meningoencephalitis: Severe cases may receive 6 months authorization.

    HLH / Macrophage Activation Syndrome (MAS)

    Authorization of 6 months may be granted when ALL of the following are met:

    HLH/MAS hypogammaglobulinemia: Treatment of hypogammaglobulinemia in HLH or MAS when total IgG is less than 400 mg/dL or two standard deviations below the mean for age.IgG < 400 mg/dL or < -2 SD for age

    Hemolytic Disease of the Newborn

    Authorization of 6 months may be granted for isoimmune hemolytic disease in neonates.

    Hemolytic disease of newborn: Isoimmune hemolytic disease in neonates may receive 6 months authorization.

    Indications with authorization durations and specific criteria

    Authorization may be granted for the following indications with the specified durations and conditions

    Multifocal Motor Neuropathy (MMN): Listed as an indication

    Authorization details appear elsewhere in document

    Hematophagocytic Lymphohistiocytosis (HLH) or Macrophage Activation Syndrome (MAS): Authorization of 6 months may be granted for treatment of hypogammaglobulinemia in HLH or MAS when total IgG is less than 400 mg/dL or two standard deviations below the mean for age.IgG < 400 mg/dL or 2 SD below mean for age

    6 months authorization

    Hemolytic Disease of the Newborn: Authorization of 6 months may be granted for isoimmune hemolytic disease in neonates.

    6 months authorization

    HIV-associated Thrombocytopenia (pediatrics): Authorization of 6 months may be granted for pediatric members with IgG < 400 mg/dL and one of listed clinical conditions (recurrent bacterial infections despite prophylaxis; measles vaccination with residence in high-prevalence region; thrombocytopenia despite ART; chronic bronchiectasis; T4 count ≥ 200/mm3).IgG < 400 mg/dL; T4 ≥ 200/mm3

    6 months authorization

    HIV-associated Thrombocytopenia (adults): Authorization of 6 months may be granted for adult members with significant bleeding, platelet count < 20,000/mcL, and failure of RhIG in Rh-positive patients.platelet < 20,000/mcL

    6 months authorization

    Hyperimmunoglobulinemia E Syndrome: Authorization of 6 months may be granted to treat severe eczema in hyperimmunoglobulinemia E syndrome.

    6 months authorization

    Hypogammaglobulinemia from CAR-T therapy: Authorization of 6 months may be granted for members with IgG < 400 mg/dL receiving CAR-T therapy (examples of CAR-T agents listed).IgG < 400 mg/dL

    6 months authorization

    Multiple Myeloma: Authorization of 6 months may be granted for multiple myeloma in members who have recurrent, serious infections despite the use of prophylactic antibiotics.recurrent serious infections despite prophylactic antibiotics

    6 months authorization

    Neonatal Hemochromatosis (prophylaxis during pregnancy): Authorization of 6 months may be granted for prophylaxis in members who are pregnant with a history of pregnancy ending in documented neonatal hemochromatosis.history of pregnancy ending in documented neonatal hemochromatosis

    6 months authorization

    Opsoclonus-myoclonus: Authorization of 6 months may be granted for paraneoplastic opsoclonus-myoclonus-ataxia associated with neuroblastoma or refractory opsoclonus-myoclonus as last-resort treatment.refractory or paraneoplastic association

    6 months authorization

    Post-transfusion Purpura: Authorization of 1 month may be granted for post-transfusion purpura.

    1 month authorization

    Rasmussen Encephalitis: Authorization of 6 months may be granted for members whose symptoms do not improve with anti-epileptic drugs and corticosteroids.failure to improve with AEDs and corticosteroids

    6 months authorization

    Renal Transplantation (ABO incompatible or positive crossmatch): Authorization of 6 months may be granted for a member undergoing renal transplantation from a live donor with ABO incompatibility or positive cross match.ABO incompatibility or positive crossmatch

    6 months authorization

    Secondary Immunosuppression (major surgery, hematologic malignancy, burns, collagen-vascular disease): Authorization of 6 months may be granted to prevent or modify recurrent bacterial or viral infections in members with secondary immunosuppression and IgG < 400 mg/dL associated with listed causes.IgG < 400 mg/dL

    6 months authorization

    Solid Organ Transplantation (allosensitized): Authorization of 6 months may be granted for solid organ transplantation for allosensitized members.allosensitization status

    6 months authorization

    Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: Authorization of 1 month may be granted for severe cases.severe cases

    1 month authorization

    Toxic Shock Syndrome: Authorization of 1 month may be granted for staphylococcal or streptococcal toxic shock syndrome when infection is refractory to several hours of aggressive therapy, an undrainable focus is present, or member has persistent oliguria with pulmonary edema.refractory infection or undrainable focus or persistent oliguria with pulmonary edema

    1 month authorization

    Systemic Lupus Erythematosus (severe, active): Authorization of 6 months may be granted for severe, active SLE in members who have experienced inadequate response, intolerance or contraindication to first- and second-line therapies.inadequate response/intolerance/contraindication to 1st- and 2nd-line therapies

    6 months authorization

    Toxic Necrotizing Fasciitis Due To Group A Streptococcus: Authorization of 1 month may be granted for members with fasciitis due to invasive streptococcal infection.invasive streptococcal infection causing fasciitis

    1 month authorization

    Continuation and reauthorization

    Continuation of Therapy

    Continuation criteria: Authorization may be granted for continuation of therapy when either: A) For conditions with reauthorization criteria listed above, members currently receiving IG therapy meet the applicable reauthorization criteria; OR B) For all other conditions, all members (including new members) must meet initial authorization criteria.

    Continuation depends on meeting reauthorization or initial criteria

    Requests that lack documentation of required prior therapies or confirmatory diagnostic testing are implicitly excluded from coverage. Examples include absence of a pathology report or biopsy to confirm autoimmune mucocutaneous blistering disease and lack of documented trial and failure or intolerance of specified alternatives (for example, anticholinesterases or amifampridine for LEMS). Such missing documentation may result in denial because the member has not met the indication-specific criteria required for authorization.

    Intravenous Immune Globulin (IVIG) is considered not medically necessary for members who do not meet the specific criteria set forth in this policy. Authorization may only be granted when the applicable indication-specific diagnostic, timing, and prior-therapy requirements are documented and satisfied.

    For Appendix A determinations of an impaired antibody response to pneumococcal polysaccharide vaccine, therapy that was initiated while the member was an inpatient is excluded from consideration. Appendix A applies to members aged 2 years and older with documented impaired pneumococcal polysaccharide vaccine response and is not established for children under age 2.

    If a member does not meet the criteria described in the applicable indication-specific sections of this policy, IVIG is not medically necessary and will not be authorized. Providers must document the diagnostic confirmation, timing, IgG or other numeric thresholds, and prior therapy trials required by the relevant criteria to support approval.

    Billing and Coding

    Covered HCPCS/J‑codes (group 1)HCPCSCovered
    J1459Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 mg
    J1552Injection, immune globulin (Alyglo), 500 mg (effective 1/1/2025)
    J1553Injection, immune globulin (Yimmugo), 100 mg
    J1556Injection, immune globulin (Bivigam), 500 mg
    Covered HCPCS/J‑codes (group 2)HCPCSCovered
    J1557Injection, immune globulin, (Gammaplex), intravenous, nonlyophilized (e.g., liquid), 500 mg
    J1561Injection, immune globulin, (Gamunex), intravenous, non-lyophilized, (e.g., liquid), 500 mg
    J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), 500 mg
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard liquid), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1572Injection, immune globulin, (Flebogamma), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1554Injection, immune globulin, (Asceniv), 500 mg (effective 04/01/2021)
    C9072Injection, immune globulin (Asceniv), 500 mg (cancelled 04/01/2021)
    J1599Injection, immune globulin, intravenous, nonlyophilized (e.g., liquid), not otherwise specified, 500 mg
    J1576Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg (Panzyga) (effective 7/1/23)
    1–10 of 11
    1/2
    Unclassified codes for QivigyHCPCS
    J3490unclassified drugs (when specified as Qivigy [immune globulin intravenous, human-kthm])
    J3590unclassified biologic (when specified as Qivigy [immune globulin intravenous, human-kthm])
    Unclassified/crosswalk codeHCPCS
    C9399unclassified drugs or biologicals (when specified as Qivigy [immune globulin intravenous, human-kthm])
    inv-31: Serum IgG — threshold value used in multiple indications
    ThresholdSerum IgG < 400 mg/dL (or two standard deviations below the mean for age)
    Use cases referencing this thresholdBMT/HSCT prophylaxis when pretreatment IgG is low; HLH/MAS hypogammaglobulinemia; CAR-T–related hypogammaglobulinemia; secondary immunosuppression indications
    Relevance to authorizationPretreatment serum IgG < 400 mg/dL satisfies criterion (alternative to timing) for initial 6‑month prophylaxis in BMT/HSCT recipients
    inv-32: GBS symptom onset window — timing threshold for GBS
    Timing windowOnset of neurologic symptoms < 4 weeks from anticipated start of therapy
    Clinical contextApplies to severe Guillain‑Barré syndrome with significant weakness (e.g., inability to stand or walk without aid, respiratory weakness)
    Authorization impactMeets criterion for up to 2 months total authorization for GBS when onset is within this window
    inv-33: Total IgG — repeated quantitative threshold references
    Numeric thresholdTotal IgG < 400 mg/dL (or two standard deviations below the mean for age)
    Indications citing this thresholdHLH/MAS, CAR‑T therapy hypogammaglobulinemia, secondary immunosuppression, pediatric HIV criteria and other hypogammaglobulinemia–related authorizations
    Authorization duration linkedCommonly supports initial 6‑month authorization when threshold met
    inv-34: Platelet count threshold (HIV-associated thrombocytopenia, adults)
    Platelet count thresholdPlatelet count < 20,000/mcL
    PopulationAdult members with HIV‑associated thrombocytopenia
    Authorization contextUsed with significant bleeding and failure of RhIG in Rh‑positive patients to justify 6‑month IVIG authorization

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required for listed indications

    Prior authorization is required for IVIG for the listed indications; initial authorization durations are specified per indication (commonly 6 months; some indications 1–3 months or 2 months total). Providers must request prior authorization before IVIG is approved and follow the indication-specific duration noted in the criteria (e.g., 6 months for BMT/HSCT prophylaxis, 3 months for MMN, 2 months total for GBS, 1 month for Kawasaki).

    • Initial authorization durations are indication-specific (examples: 6 months for many indications; 3 months for MMN; 2 months total for GBS; 1 month for Kawasaki).
    • Continuation/reauthorization requires meeting the reauthorization criteria listed for the condition or initial criteria for other conditions.
    Prior Authorization

    Prior authorization with indication-specific criteria and duration

    Prior authorization must meet the specific clinical criteria and duration for the indication before IVIG will be approved; continuation requires meeting reauthorization criteria when listed. Providers should ensure the submitted request maps to the indication-specific criteria (typical durations: 1 or 6 months depending on diagnosis).

    • Prior authorization decisions are based on indication-specific criteria and duration.
    • Continuation of therapy granted only when reauthorization criteria or initial criteria are met.
    Billing Rule

    Prior authorization and required HCPCS/J‑code billing

    Authorization and approvals may be constrained by dosing limits and require billing of IVIG administrations using the specified HCPCS/J‑codes; include product‑specific codes (including J‑codes and unclassified codes for Qivigy) on claims.

    • Report IVIG administrations using the listed HCPCS/J‑codes (product-specific J‑codes such as J1459, J1557, J1561, etc.).
    • When Qivigy is specified, use J3490/J3590 or C9399 as applicable per guidance in the coding section.
    Step Therapy

    Document trial and failure/intolerance of first‑line therapies

    For multiple indications, providers must document a trial and failure or intolerance of first-line therapies before IVIG will be authorized (examples include anticholinesterases/amifampridine for LEMS; corticosteroids or immunosuppressives for blistering disease; corticosteroids or splenectomy for autoimmune hemolytic anemia; GCSF for autoimmune neutropenia).

    • LEMS: anticholinesterases and amifampridine must have been tried and were unsuccessful or not tolerated.
    • Autoimmune mucocutaneous blistering disease: failure or significant complications from corticosteroids/immunosuppressives required.
    • Autoimmune hemolytic anemia: nonresponse to corticosteroids or splenectomy required.
    • Autoimmune neutropenia: GCSF unsuitable required.
    Step Therapy

    Reserve IVIG after standard therapies fail or are contraindicated

    IVIG is reserved for use after failure, intolerance, or contraindication to first‑ and second‑line therapies for some conditions (e.g., severe, active SLE and other listed diagnoses); providers must demonstrate prior standard treatments were inadequate or not tolerated.

    • SLE: authorization of 6 months may be granted only after inadequate response, intolerance, or contraindication to first‑ and second‑line therapies.
    • Adult HIV-associated thrombocytopenia: IVIG considered when RhIG has failed in Rh‑positive patients and criteria for bleeding/platelet count met.
    Note

    Dosing and administration note (source reference)

    (See source for specific language and context.)

    Documentation Required

    Required diagnostic confirmation documentation

    Provide confirmatory diagnostic documentation with the prior authorization: examples include neurophysiology studies or a positive anti‑P/Q type voltage‑gated calcium channel antibody for LEMS, and biopsy with pathology report for autoimmune mucocutaneous blistering disease.

    • LEMS: neurophysiology (e.g., electromyography) OR positive anti‑P/Q antibody required.
    • Blistering disease: diagnosis proven by biopsy and confirmed by pathology report.
    Documentation Required

    Provide supporting clinical information (severity, timing, IgG, prior response)

    Include supporting clinical information to justify the request: severity and timing (e.g., GBS symptom onset < 4 weeks), response to prior therapies, pretreatment serum IgG levels (e.g., for BMT/HSCT prophylaxis), and measures of clinical benefit for reauthorization (e.g., reduction in infection frequency).

    • GBS: onset of neurologic symptoms < 4 weeks from anticipated start of therapy.
    • BMT/HSCT prophylaxis: provide pretreatment serum IgG if used to meet criteria.
    • Reauthorization: document demonstrated reduction in frequency of bacterial infections for BMT/HSCT prophylaxis.
    Documentation Required

    Provide required clinical evidence and numeric thresholds (e.g., IgG < 400 mg/dL)

    Ensure documentation meets numeric thresholds when specified (for example, total IgG < 400 mg/dL or two standard deviations below the mean for age for HLH/MAS, CAR‑T related hypogammaglobulinemia, and other hypogammaglobulinemia indications).

    • HLH/MAS and certain secondary immunosuppression indications require total IgG < 400 mg/dL (or < -2 SD for age).
    • CAR‑T related hypogammaglobulinemia requires IgG < 400 mg/dL for authorization.
    Billing Rule

    Billing: report IVIG with specified HCPCS/J‑codes (product‑specific guidance for Qivigy)

    Report IVIG administrations using the listed HCPCS/J‑codes on claims; when Qivigy is specified, use the unclassified HCPCS entries (J3490/J3590) or C9399 as noted in the coding guidance.

    • Use product‑specific J‑codes from the coding lists (e.g., J1459, J1557, J1561, J1577 where applicable).
    • If Qivigy is specified, bill with J3490/J3590 or C9399 per the coding notes.
    Denial Risk

    BMT/HSCT prophylaxis: meet timing (≤100 days) or pretreatment IgG criteria

    For BMT/HSCT prophylaxis, requests must meet timing or IgG criteria: IG must be requested within the first 100 days post‑transplant OR the member must have pretreatment serum IgG < 400 mg/dL; requests outside these parameters risk denial.

    • Initial authorization of 6 months granted only when IG is requested within first 100 days post‑transplant OR pretreatment serum IgG < 400 mg/dL.
    • Reauthorization requires demonstration of reduced bacterial infection frequency.
    Denial Risk

    Diagnostic confirmation required — missing tests risk denial

    Requests lacking required confirmatory diagnostic testing may be denied; examples include absence of neurophysiology or anti‑P/Q antibody testing for LEMS, or missing biopsy/pathology for autoimmune mucocutaneous blistering disease.

    • LEMS: must have neurophysiology studies or positive anti‑P/Q antibody documented.
    • Blistering disease: biopsy and pathology report required.
    Denial Risk

    Denial risk if policy criteria are not met

    Intravenous Immune Globulin is considered not medically necessary and may be denied when the member does not meet the criteria set forth in the policy (including indication criteria, prior therapy requirements, diagnostic confirmation, or numeric thresholds).

    • If initial or reauthorization criteria are not met, IVIG is not medically necessary.
    • Ensure all condition‑specific requirements are documented to avoid denial.
    Denial Risk

    Approvals may be subject to dosing limits per labeling/guidelines

    Approvals may be subject to dosing limits consistent with FDA‑approved labeling, accepted compendia, and evidence‑based practice guidelines; providers should anticipate that dosing limits could affect authorization decisions.

    • Dosing and administration approvals may be constrained by labeling, compendia, or guidelines.
    • Confirm proposed dosing conforms to FDA‑approved or evidence‑based limits.

    Background

    This section provides indication-specific clinical authorization criteria for intravenous immune globulin (IVIG) across a range of immune-mediated, infectious, and transplant-related conditions. It specifies required diagnostic confirmation, timing relative to disease course or transplant, prior-therapy requirements, and numeric thresholds (for example, IgG < 400 mg/dL where listed) that must be met for initial authorization and reauthorization.

    Definitions and Appendix References

    inv-50: BMT/HSCT recipients — definition and timing window for prophylactic IVIG
    DefinitionBMT/HSCT recipients: bone marrow transplant / hematopoietic stem cell transplant recipients for whom prophylactic IVIG is prescribed to prevent bacterial infections
    Timing window for prophylaxisIG requested within the first 100 days post‑transplant qualifies as an authorization criterion
    Alternate qualifying criterionMember has a pretreatment serum IgG < 400 mg/dL (alternative to the 100‑day timing)
    Authorization durationInitial authorization of 6 months may be granted when criteria are met; reauthorization requires demonstration of reduced infection frequency
    inv-51: Severe Guillain-Barre Syndrome (GBS) — definition involving significant weakness and timing
    DefinitionSevere Guillain‑Barré Syndrome (GBS): GBS with significant weakness (e.g., inability to stand or walk without aid, respiratory weakness)
    Timing requirementOnset of neurologic symptoms must be less than 4 weeks from the anticipated start of therapy
    Authorization implicationMeets criteria for up to 2 months total authorization when both severity and timing requirements are satisfied
    inv-52: Hypogammaglobulinemia threshold — Total IgG < 400 mg/dL or two SD below mean for age
    Hypogammaglobulinemia thresholdTotal IgG < 400 mg/dL or two standard deviations below the mean for age
    UsesEligibility criterion for IVIG in HLH/MAS, CAR‑T–related hypogammaglobulinemia, secondary immunosuppression, and pediatric indications
    Authorization durationTypically supports a 6‑month initial authorization when met
    inv-53: Appendix A — Impaired antibody response to pneumococcal polysaccharide vaccine
    DefinitionImpaired antibody response to pneumococcal polysaccharide vaccine demonstrated in persons age ≥ 2 years
    Age noteNot established for children under 2 years of age
    ExclusionTherapy initiated in the hospital setting is excluded from defining impaired antibody response for this appendix
    inv-54: Appendix B — Examples of bleeding risk factors
    Examples of bleeding risk factorsUndergoing a medical or dental procedure where blood loss is anticipated
    ComorbiditiesComorbid conditions such as peptic ulcer disease or hypertension that increase bleeding risk
    Other risk factorsMandated anticoagulation therapy or professions/lifestyles that predispose to trauma (e.g., construction worker, firefighter, professional athlete)